As of September 30, 2026, SANUWAVE Health, Inc. carries a market capitalization of 40.52M, placing it among publicly traded companies globally. Its enterprise value stands at 53.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 40.52M |
| Enterprise Value | 53.55M |
SANUWAVE Health, Inc.'s next confirmed earnings release is scheduled for March 19, 2027.
| Earnings Date | 3/19/2027 |
As of September 30, 2026, SANUWAVE Health, Inc. has 8.60M shares outstanding.
| Shares Outstanding | 8.60M |
As of September 30, 2026, SANUWAVE Health, Inc. trades at a trailing price-to-earnings ratio of 15.74. The price-to-sales ratio is 0.99, and the price-to-book ratio stands at 14.22.
| PE Ratio | 15.74 |
| PS Ratio | 0.99 |
| PB Ratio | 14.22 |
| P/TBV Ratio | -5.70 |
| P/FCF Ratio | 16.50 |
| P/OCF Ratio | 12.31 |
These figures are as of September 30, 2026. The EV/Sales ratio of 1.31 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. SANUWAVE Health, Inc. trades at an EV/FCF ratio of 11.99, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 53.55M versus a market cap of 40.52M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 1.31 |
| EV / FCF | 11.99 |
As of September 30, 2026, SANUWAVE Health, Inc. maintains a current ratio of 1.18, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 687.96, indicating elevated leverage, while an interest coverage ratio of -0.12 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.18 |
| Quick Ratio | 0.70 |
| Debt / Equity | 687.96 |
| Debt / EBITDA | -74.27 |
| Interest Coverage | -0.12 |
These figures cover the twelve months ended September 30, 2026. Return on invested capital (ROIC) is negative at -8.43, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 7.55, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 21.17, useful for judging operating efficiency across full business cycles. The company generates approximately 746,018.18 in revenue per employee across its workforce of 55.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.45 indicates how many times SANUWAVE Health, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | 7.55 |
| Return on Invested Capital (ROIC) | -8.43 |
| Return on Capital Employed (ROCE) | 21.17 |
| Revenue Per Employee | 746,018.18 |
| Employee Count | 55.00 |
| Inventory Turnover | 1.45 |
Over the twelve months ended September 30, 2026, SANUWAVE Health, Inc. recorded 69,000.00 in income tax expense. That works out to an effective tax rate of 2.53, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.73M, leaving 2.57M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 69,000.00 |
| Effective Tax Rate | 2.53 |
As of the close on November 16, 2026, SANUWAVE Health, Inc.'s stock has declined approximately 94.51% over the past 52 weeks. The 50-day moving average sits at 4.46, while the 200-day moving average is 12.17.
| 52-Week Price Change | -94.51% |
| 50-Day Moving Average | 4.46 |
| 200-Day Moving Average | 12.17 |
Over the twelve months ended September 30, 2026, SANUWAVE Health, Inc. generated 41.03M in revenue and converted that into 2.57M in net income, yielding earnings per share of 0.31. EBITDA reached -264,000.00, while operating income came in at -1.86M.
| Revenue | 41.03M |
| Gross Profit | 31.19M |
| Operating Income | -1.86M |
| Pretax Income | 2.73M |
| Net Income | 2.57M |
| EBITDA | -264,000.00 |
| EBIT | -1.86M |
| Earnings Per Share (EPS) | 0.31 |
As of September 30, 2026, SANUWAVE Health, Inc. holds 6.57M in cash and equivalents against 19.61M in total debt, resulting in a net debt position of 11.59M. Total book value stands at 2.85M, with working capital of 2.91M providing operational flexibility.
| Cash & Cash Equivalents | 6.57M |
| Total Debt | 19.61M |
| Net Debt | 11.59M |
| Equity (Book Value) | 2.85M |
| Book Value Per Share | 0.33 |
| Working Capital | 2.91M |
SANUWAVE Health, Inc. produced 3.29M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -907,000.00 in capital expenditures, free cash flow totaled 2.38M - equivalent to 0.28 per share.
| Operating Cash Flow | 3.29M |
| Capital Expenditures | -907,000.00 |
| Free Cash Flow | 2.38M |
| FCF Per Share | 0.28 |
Over the twelve months ended September 30, 2026, SANUWAVE Health, Inc. posted a gross margin of 76.01, reflecting its pricing power and cost economics. The operating margin of -4.54 and net profit margin of 6.27 provide insight into operational efficiency.
| Gross Margin | 76.01 |
| Operating Margin | -4.54 |
| Pretax Margin | 6.65 |
| Profit Margin | 6.27 |
| EBITDA Margin | -0.64 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 6.06, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 14.29, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to SANUWAVE Health, Inc. shareholders.
| Shareholder Yield | 14.29 |
| FCF Yield | 6.06 |
SANUWAVE Health, Inc.'s most recent stock split took place on October 18, 2024 with a 375:1 split ratio.
| Last Split Date | 10/18/2024 |
| Split Ratio | 375:1 |
As of September 30, 2026, SANUWAVE Health, Inc. has an Altman Z-Score of -12.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.76 |